HUMAN NOROVIRUS GII.2-SPECIFIC ANTIBODY

WIPO Patent Application WO/2023/182244

A1

The purpose of the present invention is to provide an antibody which inhibits the infection of cells with human norovirus (HuNoV) GII.2. More specifically, the present invention relates to a VHH antibody which binds to human norovirus (HuNoV) GII.2 and inhibits the infection of intestinal cells with HuNoV GII.2. More specifically, the present invention relates to a VHH antibody which inhibits the infection of intestinal cells with HuNoV GII.2, the VHH antibody being characterized in that the amino acid sequences of complementarity-determining regions 1 to 3 (CDR1, CDR2 and CDR3) are the following (A), (B), (C), (D), (E) or (F). (A) CDR1 containing the amino acid sequence represented by SEQ ID NO: 7, CDR2 containing the amino acid sequence represented by SEQ ID NO: 8, and CDR3 containing the amino acid sequence represented by SEQ ID NO: 9. (B) CDR1 containing the amino acid sequence represented by SEQ ID NO: 10, CDR2 containing the amino acid sequence represented by SEQ ID NO: 11, and CDR3 containing the amino acid sequence represented by SEQ ID NO: 12. (C) CDR1 containing the amino acid sequence represented by SEQ ID NO: 13, CDR2 containing the amino acid sequence represented by SEQ ID NO: 14, and CDR3 containing the amino acid sequence represented by SEQ ID NO: 15. (D) CDR1 containing the amino acid sequence represented by SEQ ID NO: 16, CDR2 containing the amino acid sequence represented by SEQ ID NO: 17, and CDR3 containing the amino acid sequence represented by SEQ ID NO: 18. (E) CDR1 containing the amino acid sequence represented by SEQ ID NO: 19, CDR2 containing the amino acid sequence represented by SEQ ID NO: 20, and CDR3 containing the amino acid sequence represented by SEQ ID NO: 21. (F) CDR1 containing the amino acid sequence represented by SEQ ID NO: 22, CDR2 containing the amino acid sequence represented by SEQ ID NO: 23, and CDR3 containing the amino acid sequence represented by SEQ ID NO: 24.

WO/2022/007807	BISPECIFIC ANTIBODY AND USE THEREOF
JP6949025	Antibodies to risperidone and its use
JP2022121630	COMPOSITION AND METHOD FOR INTERNAL TRANSITION ENZYME

YUKI YOSHIKAZU (JP)
KIYONO HIROSHI (JP)
SATO SHINTARO (JP)

PCT/JP2023/010780

September 28, 2023

March 20, 2023

Click for automatic bibliography generation  

HANAVAX INC (JP)
UNIV TOKYO (JP)
UNIV OSAKA (JP)

C12N15/13; A01H6/46; A61K39/395; A61P31/12; C07K16/10; C12N1/21; C12N15/63

WO2018181866A1

2018-10-04

JP2010513245A	2010-04-30
JP2009506095A	2009-02-12

YUKI YOSHIKAZU, KUROKAWA SHIHO, SATO SHINTARO, SASOU AI, MATSUMOTO NAOMI, SUZUKI AKIO, SAKON NAOMI, GODA YUKI, TAKEYAMA NATSUMI, M: "A Heterodimeric Antibody Fragment for Passive Immunotherapy Against Norovirus Infection", JOURNAL OF INFECTIOUS DISEASES, UNIVERSITY OF CHICAGO PRESS, US, vol. 222, no. 3, 6 July 2020 (2020-07-06), US , pages 470 - 478, XP093095181, ISSN: 0022-1899, DOI: 10.1093/infdis/jiaa115
THONGPRACHUM, AKSARA ET AL.: "Emergence of norovirus GII.2 and its novel recombination during the gastroenteritis outbreak in Japanese children in mid-2016", INFECTION, GENETICS AND EVOLUTION, vol. 51, 2017, pages 86 - 88, XP085023777, DOI: 10.1016/j.meegid.2017.03.020
YU JIE-MEI: "What is the Potential Cause for the Predominance of GII.2[P16] Norovirus in Acute Gastroenteritis Outbreaks in China?", CHINA CDC WEEKLY, vol. 4, no. 2, 1 January 2022 (2022-01-01), pages 27 - 30, XP093095182, ISSN: 2096-7071, DOI: 10.46234/ccdcw2022.003

OKUHARA Koji (JP)

View/Download PDF      PDF Help

Previous Patent: GENE EXPRESSION REGULATOR, PROPHYLACTIC DRUG OR THERAPEUTIC DRUG FOR ALZHEIMER'S DISEASE, AND METHOD...

Next Patent: LIQUID CRYSTAL DISPLAY ELEMENT SEALANT AND LIQUID CRYSTAL DISPLAY ELEMENT